arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

Eloxx Pharmaceuticals, Inc.

ELOX
$12.82 ▼ -0.14 (-1.08%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
27 Visible periods
26 Metrics
Peer-ranked Benchmarks
Price Chart
78
Health
Good
Bullish
auto_awesome

Analytical Summary

Eloxx Pharmaceuticals, Inc. shows strong fundamentals with top-quartile Return on Common Equity (%) and Debt to Equity. The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $33.0M
Dividend Yield —
Revenue Growth None
Op. Margin —
ROIC 80.0% ↗
FCF / Share $-5.58 ↗
Trailing P/E —
Price / Book —
FCF Yield —
Debt / Equity -0.04
info Valuation on last close. End-of-day price, Nov 5, 2026.

27-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
↓ -100.0% —
Net Income Profit after all expenses
$-17.05M
↑ +52.7% —
FCF / Share Free cash flow per share
$-5.58
↑ +62.1% —
Long-Term Debt Long-term obligations
$1.00M
↓ -91.5% —
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Returns
98
Financial Health ↑
63
Cash Quality ↑
57

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 27 years · 69 quarters